Abstract OBJECTIVE To evaluate the emerging role of obesity pharmacotherapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and multi-agonists, in osteoarthritis (OA) management, by examining the interpretation of pain outcomes, potential structural joint effects, the importance of weight-loss quality, implications for time to total joint replacement (TJR), and the patient populations most likely to benefit from […]
Can obesity pharmacotherapy modify osteoarthritis? Interpreting pain relief, weight-loss quality, and structural outcomes.
September 21, 2026
Osteoarthritis Cartilage